Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale…
MaaT PharmaSeptember 18, 2018
MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase…
MaaT PharmaMarch 5, 2018
The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer…
MaaT PharmaNovember 30, 2017
Maat Pharma has reached the target number of patients to be treated in its first…
MaaT PharmaJuly 20, 2017
Quality, safety and reproducibility: more than a medical device, a technological breakthrough in the field…
MaaT PharmaJune 15, 2017
Les Transferts de Microbiote Fécal (TMF) sont aujourd’hui utilisés afin de traiter certaines pathologies de…
MaaT PharmaMay 16, 2017
Les Transferts de Microbiote Fécal (TMF) sont aujourd’hui utilisés afin de traiter certaines pathologies de…
MaaT PharmaApril 20, 2017